Ajanta Pharma net zooms by 36% in Q3, plans sub-division of shares

Ajanta Pharma, a Rs.1,000 crore Mumbai based pharma major, has posted impressive performance during the third quarter ended December 2014 with new launches. Its net profit has taken a quantum jump of 35.7 per cent to Rs.84.71 crore from Rs.62.42 crore in the corresponding period of last year. Its net sales also went up by 21.8 per cent to Rs.356.28 crore from Rs.292.59 crore. With strong growth in bottomline, its EPS improved to Rs.24.08 from Rs.17.75. Exports contributed 61 per cent of the revenue for the December quarter.

The Board of Directors has approved sub-division of nominal value of equity shares of the company from Rs.5/- each to nominal value of Rs.2/- each. With strong performance and announcement of sub-division, Ajanta Pharma scrip improved by 11 per cent or over Rs.264 in the afternoon session on BSE to Rs.2660.

Rajesh Agrawal, joint managing director, says, “We are pleased with the results of yet another sound quarter. All our growth drivers are performing as per our plans and expectations. We continue to post above industry growth in India and emerging markets in our branded generic business segment. Our Dahej formulation facility (oral solids) implementation has been completed and is undergoing qualification. We expect to take regulatory filing batches from Q1 of FY'16 onwards. Addition of this facility will ensure that we have adequate capacities to cater to our growths in coming years.”

For the nine months ended December 2014, Ajanta's net sales increased by 24.3 per cent to Rs.968 crore from Rs.779 crore in the similar period of last year. Its net profit went up sharply by 47.3 per cent to Rs.222 crore from Rs 151 crore. EBDITA moved up by 42 per cent to Rs.332 crore. EPS worked out to Rs 63.13 as against Rs.42.89 in the last period. Exports contributed 61 per cent of total operating income for the nine months.

Marksans Pharma net jumps up by 56% to Rs. 31 cr

Marksans Pharma has posted impressive performance during the second quarter ended September 2014 and its consolidated net profit increased by 55.7 per cent to Rs. 31.16 crore from Rs. 20.01 crore in the similar period of last year. Its EBDITA also moved up by 71.8 per cent to Rs. 50.96 crore from Rs. 29.66 crore. EPS worked out to Rs. 0.82 as against Rs. 0.53 in the last period.

The company's consolidated net sales for the first six months ended September 2014 increased by 35.3 per cent to Rs. 413 crore from Rs. 305 crore and its net profit moved up by 46 per cent to Rs. 56.63 crore from Rs. 38.79 crore in the corresponding period of last year. Its formulations business in Europe increased by 43 per cent to Rs. 271.20 crore from Rs. 189.70 crore and its US & North America formulation revenue improved by 46.7 per cent to Rs. 76.46 crore. Its revenue in Australia and New Zealand touched to Rs. 41.10 crore.

ndoco Remedies net jumps by 40% to Rs.22.41 cr in Q2

Indoco Remedies, a Rs.700 crore plus pharma major from Mumbai, has posted satisfactory performance during the second quarter ended September 2014 and its net profit moved up by 39.7 per cent to Rs.22.41 crore from Rs.16.04 crore in the corresponding period of last year. Its EBDITA also improved sharply by 73.9 per cent to Rs.49.19 crore from Rs.33.44 crore. The company's standalone net sales improved by 16.1 per cent to Rs.226.42 crore from Rs.195.05 crore. With higher profit, its EPS worked out to Rs.2.43 as compared to Rs.1.74 in the last period.

The company's domestic sales increased to Rs.144.69 crore from Rs.127.59 crore, a growth of 13.4 per cent and its international sales went up by 21.2 per cent to Rs.81.73 crore from Rs.67.46 crore. The company launched six new products in the domestic market. Indoco's European sales contributed 61.9 per cent and US sales 21.9 per cent to its international sales.